TNFRSF1B and diabetic kidney disease: Although novel biomarkers such as KIM-1 and TNFR2 have not yet been established as standalone surrogate endpoints for DKD, their predictive utility may be enhanced when used in conjunction with established markers, such as eGFR slope and UACR change, to improve risk prediction for ESRD.